Novel tetrapeptide compound as well as preparation method and application thereof

By developing a new tetrapeptide compound hexanoyl-L-tyrosyl-L-isoleucine aminocaproamide and optimizing the structure of angiotensin IV receptor antagonists, we solved the biological problems of existing angiotensin IV receptor antagonists. It solves the problem of insufficient activity and achieves effective regulation of blood pressure and blood flow to meet clinical needs.

CN104788537AInactive Publication Date: 2015-07-22CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
2 Cites 2 Cited by

Patent Information

Application Number
CN201510144356.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2015-03-31
Publication Date
2015-07-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing angiotensin IV receptor antagonists have limitations in regulating blood pressure and blood flow, and have insufficient biological activity, making it difficult to meet clinical needs.

Method used

Develop a new tetrapeptide compound hexanoyl-L-tyrosyl-L-isoleucyl aminocaproamide, and optimize its structure through the combination of tyrosyl-isoleucyl active fragment and aminocaproamide fragment to improve Biological activity of angiotensin IV receptor antagonists.

Benefits of technology

The tetrapeptide compound shows significant angiotensin IV receptor antagonist activity, can effectively regulate blood pressure and blood flow, improve biological activity, and meet clinical application needs.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a novel tetrapeptide compound as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The novel tetrapeptide compound is caproyl-L-tyrosyl-L-isoleucyl amino caproamide, and the structural formula is as shown in the formula 1 in the description. As the tetrapeptide compound comprises an active fragment tyrosyl-isoleucyl, the dipeptide is always taken as the active fragment used as a novel angiotensin IV receptor antagonist, on the basis of the structural characteristics of the active dipeptide, hexanoyl fragments are introduced to one side of tyrosyl, and amino caproamide fragments with good bioactivity are further introduced to one side of isoleucine, caproyl-L-tyrosyl-L-isoleucyl amino caproamide is finally obtained, and the novel tetrapeptide compound can be used as the novel angiotensin IV receptor antagonist.
Need to check novelty before this filing date? Find Prior Art